AstraZeneca's FARXIGA (Dapagliflozin) Secures FDA Approval To Improve Glycemic Control In Pediatric Patients With Type-2 Diabetes Aged 10 Years And Older
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's FARXIGA (Dapagliflozin) has received FDA approval to improve glycemic control in pediatric patients with Type-2 Diabetes aged 10 years and older. This approval is based on positive results from the pediatric T2NOW Phase III trial.
June 12, 2024 | 9:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's FARXIGA has received FDA approval for use in pediatric patients with Type-2 Diabetes, expanding its market and potential revenue.
The FDA approval for pediatric use of FARXIGA significantly expands the drug's market, potentially increasing AstraZeneca's revenue. The positive results from the T2NOW Phase III trial support the drug's efficacy, likely boosting investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100